Wockhardt receives USFDAs final approval for Olopatadine HCl solution

Mumbai, July 26, 2017: Pharma Major, Wockhardt has received final approval from United States Food and Drug Administration (USFDA) for its ANDA for 0.1 percent ophthalmic solution of Olopatadine HCI. Olopatadine HCl eye drops used for the treatment of opthalmic allergies, company said in a filing with BSE The eye drop Olopatadine HCI 0.1 percent ophthalmic solution is a generic version of Patanol, marketed at US by Alcon, a subsidiary of Novartis. The product will be manufactured at USFDA approved contract manufacturing organization based in Montreal, Canada.